CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03967951|
Recruitment Status : Recruiting
First Posted : May 30, 2019
Last Update Posted : June 3, 2019
|Condition or disease||Intervention/treatment|
|Pancreatic Neuroendocrine Tumor||Other: CT radiomic feature evaluation|
CT imaging is the most widely used modality for studying radiomic features due to its ability to assess tissue density, shape, texture and size before, during and after therapy. To the best of the investigator's knowledge, the impact of inter-observer delineation variability on the reliability of CT RF for PanNEN patients, including Hounsfield unit (HU) values-, shape-, and texture-based features, has not yet been assessed. One this has been determined, an additional evaluation will be conducted to correlate the morphologically observed images with their histopathological characteristics.
The ultimate potential objective of this research is to identify and predict characteristics of aggressiveness of PanNEN in CT scans.
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms|
|Actual Study Start Date :||March 23, 2019|
|Estimated Primary Completion Date :||November 28, 2019|
|Estimated Study Completion Date :||December 28, 2019|
- Other: CT radiomic feature evaluation
Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.
In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.
Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated.
- Interobserver variability in delineating panNENs on CT [ Time Frame: 6 months ]Asses inter-observer variability on CT- scans (with contrast alone)
- Use CT texture analysis to predict, histological characteristics of PanNEN on CT scans [ Time Frame: 6 months ]Evaluate histological characteristics on CT-scans with and without contrast agent in a group of subjects
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03967951
|Contact: Francesco De Cobelli, MDemail@example.com|
|Contact: Stephanie Steidler, PhDfirstname.lastname@example.org|
|Deaprtment of Radiology, IRCCS Ospadale San Raffaele||Recruiting|
|Milano, Italy, 20132|
|Contact: Stephanie Steidler, PhD +390226436111 email@example.com|
|Principal Investigator: Francesco De Cobelli, MD|
|Sub-Investigator: Fiorino Claudio, MSc|
|Sub-Investigator: Mori Martina, MSc|
|IRCCS Ospedale San Raffaele||Recruiting|
|Milano, Italy, 20153|
|Contact: Stephanie Steidler firstname.lastname@example.org|